NCT05551130

Brief Summary

The aim of this study is to compare the clinical and radiographic efficacy of Equia system bulk fill glass hybrid material with composite resins in the permanent restoration of pediatric patients' permanent teeth.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
44

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Aug 2020

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2020

Completed
15 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 16, 2020

Completed
12 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2021

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

September 19, 2022

Completed
3 days until next milestone

First Posted

Study publicly available on registry

September 22, 2022

Completed
Last Updated

September 26, 2022

Status Verified

September 1, 2022

Enrollment Period

15 days

First QC Date

September 19, 2022

Last Update Submit

September 22, 2022

Conditions

Keywords

Composite ResinsClinical TrialGlass Ionomer CementsPermanent Dental Restoration

Outcome Measures

Primary Outcomes (7)

  • marginal adaptation

    According to the amended USPHS (United States Public Health Service) criteria, a direct clinical evaluation was conducted. The scale: Alfa Bravo Charlie

    2 weeks-12 months

  • marginal discoloration

    According to the amended USPHS (United States Public Health Service) criteria, a direct clinical evaluation was conducted. The scale: Alfa Bravo Charlie

    2 weeks-12 months

  • color match

    According to the amended USPHS (United States Public Health Service) criteria, a direct clinical evaluation was conducted. The scale: Alfa Bravo Charlie

    2 weeks-12 months

  • surface texture

    According to the amended USPHS (United States Public Health Service) criteria, a direct clinical evaluation was conducted. The scale: Alfa Bravo Charlie

    2 weeks-12 months

  • secondary caries

    According to the amended USPHS (United States Public Health Service) criteria, a direct clinical evaluation was conducted. The scale: Alfa Bravo Charlie

    2 weeks-12 months

  • postoperative sensitivity

    According to the amended USPHS (United States Public Health Service) criteria, a direct clinical evaluation was conducted. The scale: Alfa Bravo Charlie

    2 weeks-12 months

  • retention

    According to the amended USPHS (United States Public Health Service) criteria, a direct clinical evaluation was conducted. The scale: Alfa Bravo Charlie

    2 weeks-12 months

Secondary Outcomes (1)

  • anatomic form

    2 weeks-12 months

Study Arms (2)

Equia Group

ACTIVE COMPARATOR

Equia system bulk fill glass hybrid material

Other: Restoration

Charisma Group

ACTIVE COMPARATOR

Charisma Smart universal composite resin

Other: Restoration

Interventions

Restorations completed with these materials.

Also known as: Restorative Interventions
Charisma GroupEquia Group

Eligibility Criteria

Age8 Years - 16 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • The patient has no systemic disease
  • The patient should have good periodontal status
  • Teeth to be restored should be symptomless and vital
  • Teeth to be restored should have proximal contacts on both mesial and distal surfaces and be in occlusion with the antagonist teeth
  • Teeth that have class II caries lesions in external and middle 1/3 of dentine thickness radiographically

You may not qualify if:

  • Xerostomia and bruxism;
  • Absence of adjacent and antagonist teeth;
  • Extremely poor oral hygiene, severe or chronic periodontitis;
  • Teeth that have any restoration, endodontic treatment, periodontal and periapical pathology.
  • The patients who are undergoing orthodontic treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Merve Abakli Inci

Konya, 42090, Turkey (Türkiye)

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assist. Prof.

Study Record Dates

First Submitted

September 19, 2022

First Posted

September 22, 2022

Study Start

August 1, 2020

Primary Completion

August 16, 2020

Study Completion

August 1, 2021

Last Updated

September 26, 2022

Record last verified: 2022-09

Data Sharing

IPD Sharing
Will not share

The research will be published soon.

Locations